Genetic susceptibility to adverse drug effects - Epidemiology ...

More documents

Recommendations

Info

Common ABCB1 variants increase QTc shortening and risk of SCD in digoxin users 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. Med 1990;29(4):346-53. Willems JL, Abreu-Lima C, Arnaud P, et al. The diagnostic performance of computer programs for the interpretation of electrocardiograms. N Engl J Med 1991;325(25):1767-73. de Bruyne MC, Kors JA, Hoes AW, et al. Diagnostic interpretation of electrocardiograms in population-based research: computer program research physicians, or cardiologists? J Clin Epidemiol 1997;50(8):947-52. Drugs that Prolong the QT Interval and/or Induce Torsades de Pointes Ventricular Arrhythmia. In: The University of Arizona Center for Education and Research on Therapeutics, Arizona Health Sciences Center, Tucson, Arizona. Abecasis GR, Cookson WO. GOLD--graphical overview of linkage disequilibrium. Bioinformatics 2000;16(2):182-3. Stram DO, Leigh Pearce C, Bretsky P, et al. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003;55(4):179-90. Schaid DJ. Evaluating associations of haplotypes with traits. Genet Epidemiol 2004;27(4):348-64. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multi<strong>drug</strong> resistance transporter) gene. Pharmacogenetics 2003;13(8):481-94. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75(1):13-33. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein <strong>drug</strong> transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69(3):169-74. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70(2):189-99. Tang K, Wong LP, Lee EJ, et al. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 2004;13(8):783-97. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “Silent” Polymorphism in the MDR1 Gene Changes Substrate Specificity. Science 2006;315(5811):525-8. 57
Page 1 and 2:
Genetic susceptibility to adverse d
Page 3 and 4:
The work presented in this thesis w
Page 5:
Promotiecommissie Promotoren: Prof.
Page 10: 1 General Introduction
Page 13 and 14: Chapter 1 genome. Every SNP represe
Page 15 and 16: Chapter 1 References 1. 2. 3. 4. 5.
Page 18: 2 Quantifying the risk of adverse d
Page 21 and 22: Chapter 2 Introduction The cardiac
Page 23 and 24: Chapter 2 Table 1 Characteristics o
Page 25 and 26: Chapter 2 digoxin treatment appears
Page 27 and 28: Chapter 2 References 1. 2. 3. 4. 5.
Page 30: 3 Common variants in the ABCB1 gene
Page 33 and 34: Chapter 3.1 Introduction The ATP-Bi
Page 35 and 36: Chapter 3.1 Co-variables. Covariate
Page 37 and 38: Chapter 3.1 Table 3 Frequencies of
Page 39 and 40: Chapter 3.1 Table 5 Risk of serum d
Page 41 and 42: Chapter 3.1 Table 6 Other studies o
Page 43 and 44: Chapter 3.1 References 1. 2. 3. 4.
Page 46 and 47: 3.2 Common ABCB1 variants increase
Page 48 and 49: Common ABCB1 variants increase QTc
Page 60 and 61: 3.3 ABCB1 (MDR1) gene polymorphisms
Page 62 and 63: ABCB1 (MDR1) gene polymorphisms are
Page 72: ABCB1 (MDR1) gene polymorphisms are
Page 76 and 77: 4.1 Common NOS1AP variants are asso
Page 78 and 79: Common NOS1AP variants are associat
Page 88: Common NOS1AP variants are associat
Page 91 and 92: Chapter 4.2 Introduction Digoxin (d
Page 93 and 94: Chapter 4.2 Genotyping. All partici
Page 95 and 96: Chapter 4.2 Table 1 Baseline charac
Page 97 and 98: Chapter 4.2 Table 2 NOS1AP genotype
Page 99 and 100: Chapter 4.2 of digoxin users we fou
Page 101 and 102: Chapter 4.2 References 1. 2. 3. 4.
Page 104 and 105: 4.3 Cardiovascular drugs, NOS1AP an
Page 106 and 107: Cardiovascular drugs, NOS1AP and QT
Page 108 and 109:
Cardiovascular drugs, NOS1AP and QT
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118:
Page 121 and 122:
Chapter 4.4 Introduction Sulfonylur
Page 123 and 124:
Chapter 4.4 potentially affecting t
Page 125 and 126:
Chapter 4.4 Table 2 Average change
Page 127 and 128:
Chapter 4.4 had lower mortality rat
Page 129 and 130:
Chapter 4.4 In population based stu
Page 131 and 132:
Chapter 4.4 26. 27. 28. 29. 30. 31.
Page 134:
5 Effect of ABCB1 and NOS1AP genoty
Page 137 and 138:
Chapter 5 Introduction Digoxin is o
Page 139 and 140:
Chapter 5 Echocardiography. Our pri
Page 141 and 142:
Chapter 5 Table 1 Population charac
Page 143 and 144:
Chapter 5 Table 3 Association betwe
Page 145 and 146:
Chapter 5 Table 5 Effect of digoxin
Page 147 and 148:
Chapter 5 Discussion Digoxin is kno
Page 149 and 150:
Chapter 5 References 1. 2. 3. 4. 5.
Page 152:
6 General discussion
Page 155 and 156:
Chapter 6 2 per 1000 person years o
Page 157 and 158:
Chapter 6 cardial repolarization. B
Page 159 and 160:
Chapter 6 ated with reduced mortali
Page 161 and 162:
Chapter 6 selection bias. However,
Page 163 and 164:
Chapter 6 of the main problems is t
Page 165 and 166:
Chapter 6 References 1. 2. 3. 4. 5.
Page 167 and 168:
Chapter 6 49. 50. 51. 52. 53. 54. 5
Page 169 and 170:
Chapter 6 2007;356(11):1094-7. 101.
Page 172:
7 Summary 171
Page 175 and 176:
Chapter 7.1 2677-3435 TTT-haplotype
Page 178 and 179:
Samenvatting 7.2 Samenvatting Ondan
Page 180:
Samenvatting gereerden de regressie
Page 183 and 184:
Chapter 8 proefschrift. Verder spec
Page 186:
9 About the author Albert-Jan Aarno
Page 189 and 190:
Chapter 10 Aarnoudse ALHJ, Dieleman
show all

Genetic susceptibility to adverse drug effects - Epidemiology ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?